f22cfa82-a346-4fed-bc81-21a29bf990ee
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.690
- ANGIOGENESIS+0.580
- TNFA_SIGNALING_VIA_NFKB+0.570
- HEDGEHOG_SIGNALING+0.560
- INFLAMMATORY_RESPONSE+0.540
- IL6_JAK_STAT3_SIGNALING+0.530
- ALLOGRAFT_REJECTION+0.490
- INTERFERON_GAMMA_RESPONSE+0.450
- KRAS_SIGNALING_UP+0.440
- MYOGENESIS+0.430
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.650
- MYC_TARGETS_V1-0.560
- MYC_TARGETS_V2-0.540
- E2F_TARGETS-0.520
- DNA_REPAIR-0.430
- FATTY_ACID_METABOLISM-0.420
- PEROXISOME-0.380
- G2M_CHECKPOINT-0.310
- ADIPOGENESIS-0.290
- GLYCOLYSIS-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 67ed15bc-bbe5-4da7-81f9-002c54483f67 | — | — | 0.967 |
| 2 | 21196229-e39e-4846-be58-a1055b3ae50e | — | — | 0.960 |
| 3 | cadbc884-10b6-41e4-8aee-dc11a1453b8c | — | — | 0.951 |
| 4 | ec054d40-e5b8-496a-8c99-5e7f88f2cf37 | — | — | 0.950 |
| 5 | c277dab0-361f-4aa6-96b1-522a6e556ae1 | — | — | 0.947 |
| 6 | TCGA-CX-7085-01A-21R-2016-07 | — | — | 0.947 |
| 7 | 94f6e4f5-2447-4f1f-9f36-411f1c25a172 | — | — | 0.943 |
| 8 | b02dc7a2-3615-4b6c-a3dd-a866d8561d9d | — | — | 0.942 |
| 9 | ffe7358d-31b2-4d92-93eb-0a88abaf2dca | — | — | 0.939 |
| 10 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.937 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.690 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.580 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.570 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.560 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.540 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.530 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.490 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.440 | Inavolisib | — uncovered |
| MYOGENESIS | 0.430 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.420 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.420 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.410 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.410 | Inavolisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.370 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.360 | Inavolisib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| HYPOXIA | 0.330 | Idelalisib | — uncovered |
| APOPTOSIS | 0.310 | Idelalisib | — uncovered |